SGP · Nasdaq · CIK 0001778922

SpyGlass Pharma, Inc.

SpyGlass Pharma, Inc.’s most recent SEC filing in our snapshot is a Form 8-K filed on Oct 19, 2026. Its EDGAR record lists 29 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-$39.9M
Form 4 filings on record, past 12 months
29

Company overview

Legal name (as filed)
SpyGlass Pharma, Inc.
Ticker
SGP
SEC Central Index Key (CIK)
0001778922
Business address
IRVINE, CA
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
<br>Emerging growth company
Position in SEC ticker list
#2474 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from SpyGlass Pharma, Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2024n/aFY2025
Net income
-$29.2MFY2024-$39.9MFY2025
SGP annual results
ItemFY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue——
Net income-$29.2M-$39.9M
Diluted EPS-$16.31-$17.98
Total assets$23.3M$115.9M
Cash and equivalents$16.3M$96.4M

XBRL tags used: netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

SGP latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 26, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 6, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Oct 19, 20268-KOther events· period Oct 19, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about SpyGlass Pharma, Inc., by form type:

4 ×238-K ×7SCHEDULE 13D ×410-Q ×2SCHEDULE 13G ×210-K ×14/A ×1
SGP recent filings
FiledFormWhat it isOriginal
Oct 19, 20268-KOther events· period Oct 19, 2026Document · Index
Oct 1, 20268-KRegulation FD disclosure; Other events· period Oct 1, 2026Document · Index
Aug 6, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 6, 20268-KResults of operations· period Aug 6, 2026Document · Index
May 14, 202610-QQuarterly report· period Mar 31, 2026Document · Index
May 14, 20268-KResults of operations· period May 14, 2026Document · Index
Mar 26, 202610-KAnnual report· period Dec 31, 2025Document · Index
Mar 26, 20268-KResults of operations· period Mar 26, 2026Document · Index
Mar 9, 20268-KOther events· period Mar 9, 2026Document · Index
Feb 17, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Feb 17, 2026SCHEDULE 13DActive beneficial ownership report (over 5%)Document · Index
Feb 13, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Feb 13, 20268-KDirector or officer change· period Feb 12, 2026Document · Index
Feb 13, 2026SCHEDULE 13DActive beneficial ownership report (over 5%)Document · Index
Feb 13, 2026SCHEDULE 13DActive beneficial ownership report (over 5%)Document · Index
Feb 11, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 9, 2026Document · Index
Feb 11, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 9, 2026Document · Index
Feb 11, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 9, 2026Document · Index
Feb 11, 20264/AStatement of changes in beneficial ownership (insider trade)· period Feb 9, 2026Document · Index
Feb 11, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 9, 2026Document · Index
Feb 11, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 9, 2026Document · Index
Feb 11, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 9, 2026Document · Index
Feb 11, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 9, 2026Document · Index
Feb 11, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 9, 2026Document · Index
Feb 11, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 9, 2026Document · Index
Feb 11, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 9, 2026Document · Index
Feb 11, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 9, 2026Document · Index
Feb 11, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 9, 2026Document · Index
Feb 11, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 9, 2026Document · Index
Feb 10, 2026SCHEDULE 13DActive beneficial ownership report (over 5%)Document · Index
Feb 10, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 9, 2026Document · Index
Feb 10, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 9, 2026Document · Index
Feb 9, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 5, 2026Document · Index
Feb 9, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 5, 2026Document · Index
Feb 9, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 5, 2026Document · Index
Feb 9, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 5, 2026Document · Index
Feb 9, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 5, 2026Document · Index
Feb 9, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 5, 2026Document · Index
Feb 9, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 5, 2026Document · Index
Feb 9, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 5, 2026Document · Index

Insider filing activity

29 Form 4 filings appear in SpyGlass Pharma, Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Surgical & Medical Instruments & Apparatus

All 51 companies in Surgical & Medical Instruments & Apparatus· Companies headquartered in California

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001778922 and XBRL company facts. SpyGlass Pharma, Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.